Clinical Trials Logo
NCT number NCT03386578
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Kathryn Lypen, MPH
Phone 919-544-7040
Status Not yet recruiting
Phase Phase 2
Start date July 2018
Completion date July 2021

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics, feasibility, acceptability, and safety of a fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as oral daily pre-exposure prophylaxis (PrEP) to prevent HIV during pregnancy and postpartum in adolescents and young women and their infants.

Clinical Trial Description

This study will evaluate the pharmacokinetics, feasibility, acceptability, and safety of FTC/TDF as oral daily PrEP to prevent HIV during pregnancy and postpartum in adolescents and young women and their infants. The study will be conducted in two consecutive components: 1) Pharmacokinetics (PK) Component and 2) PrEP Comparison Component.

In the PK Component, women will be enrolled in one of two groups. Group 1 will include antepartum women at 14 to 24 weeks' gestation and Group 2 will include postpartum women who delivered 6 to 12 weeks prior to enrollment. Both groups will receive a fixed-dose combination of FTC/TDF administered once daily from Day 0 through Week 12.

In the PrEP Comparison Component, women will be enrolled in one of two cohorts. Participants in both Cohorts 1 and 2 will receive a behavioral HIV risk reduction package, including cohort-appropriate short message service (SMS) messages from Day 0 through Week 26. Cohort 1 will also receive daily oral FTC/TDF as PrEP from Day 0 through Week 26 and enhanced adherence support, including SMS messaging and feedback of drug levels with tailored counseling.

Mothers in the PK Component will have weekly study visits through Week 12 to be evaluated for drug levels and monitored for adverse effects, with their infants. Mothers in the PrEP Comparison Component will have several study visits through Week 26 (post-partum). Infants in the PrEP Comparison Component will have four study visits from birth through week 26 of life. For mothers, study visits may include physical examinations, blood and urine collection, vaginal and rectal swab collection, vaginal secretions collection, ultrasounds, and dual-energy x-ray absorptiometry (DXA) scans. For infants, study visits may include physical examinations, rectal swab and blood collection, and DXA scans.

Study Design

Related Conditions & MeSH terms

See also
  Status Clinical Trial Phase
Recruiting NCT03256435 - PrEP Intervention for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Enrolling by invitation NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2
Recruiting NCT03271307 - Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners N/A
Active, not recruiting NCT01937455 - A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults. Phase 1
Active, not recruiting NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Withdrawn NCT01975012 - Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Active, not recruiting NCT01931358 - Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E Phase 2
Completed NCT01923610 - Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B Phase 1
Completed NCT01968551 - Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults Phase 3
Recruiting NCT01439503 - Safer Sex Program for Young African-American Men Phase 2
Terminated NCT01583439 - The Mochudi Prevention Project ART Protocol N/A
Completed NCT01053598 - Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting N/A
Completed NCT01440569 - Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults Phase 3
Recruiting NCT01428596 - Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects Phase 1
Recruiting NCT01176409 - Can Valacyclovir Attenuate Inflammation in Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2? Phase 3
Recruiting NCT01204905 - R5 Integrase Study in HIV-1 Naive Patients N/A
Completed NCT01303575 - Internet-Based Sexual Health Education for Middle School Native American Youth N/A
Completed NCT00639145 - Elizabeth Glaser Pediatric AIDS Foundation Maternal Events and Pregnancy Outcomes (MEP Project)A Multi-site Protocol N/A